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Abstract
Background: Breast cancer stem cells (BCSCs) have been reported as the origin of breast cancer and the radical cause of
drug resistance, relapse and metastasis in breast cancer. BCSCs could be derived from mutated mammary epithelial stem
cells (MaSCs). Therefore, comparing the molecular differences between BCSCs and MaSCs may clarify the mechanism
underlying breast carcinogenesis and the targets for gene therapy. Specifically, the distinct miRNome data of BCSCs and
MaSCs need to be analyzed to find out the key miRNAs and reveal their roles in regulating the stemness of BCSCs.
Methods: MUC1−ESA+ cells were isolated from normal mammary epithelial cell line MCF-10A by fluorescence-activated
cell sorting (FACS) and tested for stemness by clonogenic assay and multi-potential differentiation experiments. The
miRNA profiles of MaSCs, BCSCs and breast cancer MCF-7 cells were compared to obtain the candidate miRNAs that may
regulate breast tumorigenesis. An miRNA consecutively upregulated from MaSCs to BCSCs to MCF-7 cells, miR-200c, was
chosen to determine its role in regulating the stemness of BCSCs and MaSCs in vitro and in vivo. Based on bioinformatics,
the targets of miR-200c were validated by dual-luciferase report system, western blot and rescue experiments.
Results: In a 2-D clonogenic assay, MUC1−ESA+ cells gave rise to multiple morphological colonies, including
luminal colonies, myoepithelial colonies and mixed colonies. The clonogenic potential of MUC1−ESA+ (61.5 ±
3.87 %) was significantly higher than that of non-stem MCF-10A cells (53.5 ± 3.42 %) (P < 0.05). In a 3-D matrigel
culture, MUC1−ESA+ cells grew into mammospheres with duct-like structures. A total of 12 miRNAs of interest
were identified, 8 of which were upregulated and 4 downregulated in BCSCs compared with MaSCs. In gain- and
lost-of-function assays, miR-200c was sufficient to inhibit the self-renewal of BCSCs and MaSCs in vitro and the
growth of BCSCs in vivo. Furthermore, miR-200c negatively regulated programmed cell death 10 (PDCD10) in
BCSCs and MaSCs. PDCD10 could rescue the tumorigenesis inhibited by miR-200c in BCSCs.
Discussion: Accumulating evidence shows that there is a milignant transformation from MaSCs into BCSCs. The
underlying mechanism remains unclear. In present study, miRNA profiles between MaSCs and BCSCs were
obtained. Then miRNA-200c, downregulated in both MaSCs and BCSCs, were verified as anti-oncogene, and played
essential role in regulating self-renewal of both kinds of stem-like cells. These findings reveal a novel insights of
breast tumorigenesis.
Conclusions: PDCD10 is a target gene of miR-200c and also a possible mechanism by which miR-200c plays a role
in regulating the stemness of BCSCs and MaSCs.
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transformation
* Correspondence: sunjg09@aliyun.com
1Cancer Institute of PLA, Xinqiao Hospital, Third Military Medical University,
Chongqing 400037, P. R. China
Full list of author information is available at the end of the article
© 2015 Feng et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Feng et al. BMC Cancer  (2015) 15:645 
DOI 10.1186/s12885-015-1655-5
Background
Accumulating evidence shows that tumors are organized in
a hierarchy of heterogeneous cell populations with different
biological properties and that the ability to sustain clono-
genic capacity and growth exclusively resides in a small
proportion of tumor cells termed cancer stem cells (CSCs)
or tumor-initiating cells (TICs) [1–3]. CSCs, capable of
uncontrolled growth, self-renewal and multi-lineage differ-
entiation, are the fundamental reason for drug resistance,
tumor relapse and metastasis. CSCs have been identified in
blood cancer and a number of solid tumors, including
breast cancer, through an experimental strategy that com-
bines sorting of tumor cell subpopulations based on surface
markers with functional transplantation into appropriate
animal models [4–6]. To reduce or eliminate CSCs, it is
necessary to determine the regulatory mechanism that con-
trols the expansion and self-renewal of CSCs [7].
Scientists postulate that normal stem cells with accumu-
lating mutations could initiate the process of carcinogenesis
in a majority of tumors [8]. Normal stem cells live longer
than differentiated cells and are exposed to DNA-damaging
agents for a longer time, allowing for accumulation of
epigenetic modifications or genetic mutations. Human
embryonic stem cells (hESCs) during long-term culture
acquired chromosomal changes similar to those occur-
ring in tumorigenesis and underwent deregulation of
self-renewal and dysfunction of related genes, leading
to malignant transformation [9]. It is now clear that
many pathways of normal stem cells, which guide cellular
proliferation, differentiation and apoptosis, are also promin-
ent in CSCs [1].
Breast cancer is one of the most common cancers in
adult females, accounting for 7–10 % of solid malignant
tumors, second only to cervical cancer in women. Breast
cancer stem cells (BCSCs) with biomarker of ESA+CD44+
CD24-/low [10] have been reported as the origin of different
pathological types of breast cancer and the radical cause of
drug resistance, tumor relapse and metastasis in breast
cancer. For the source of BCSCs, it has been proved that
they could be derived from mutated mammary epithelial
stem cells (MaSCs) responsible for development and dam-
age repair of breast tissue [11–13].
The above findings support the existence of BCSCs
and indicate the great significance to analyze molecular
differences in gene or RNA profiles between MaSCs
and BCSCs and reveal the mechanism of breast car-
cinogenesis. In recent years, rapid progress has been
made in research on MaSCs. Shackleton et al. [14]
found that a single cell within the Lin−CD29hiCD24+
population can reconstitute a complete mammary gland
in mice. For humans, MUC1−ESA+ epithelial cells iso-
lated from luminal epithelial cell populations of pri-
mary culture are considered as MaSCs with stem cell
properties [15].
MiRNAs are endogenously expressed non-coding RNAs
of 21–25 nt in length that interact with native coding
mRNAs to cause mRNA translation inhibition or mRNA
degradation. The regulatory roles of miRNAs in diverse
developmental and physiological events, and disease
pathogenesis have become evident in the last few years
[16, 17]. Studies demonstrated aberrant expression of miR-
NAs in several human malignancies, including leukemia,
lymphoma, lung cancer, hepatocellular cancer, colorectal
cancer, gastric cancer and breast cancer [18, 19]. MiRNAs
also play important regulatory roles in CSCs and tumori-
genesis [20–25]. Therefore, CSC-specific miRNAs would
provide valuable information for CSC properties, shedding
new light on mechanism of diverse cancers.
To investigate the roles of miRNAs in BCSC biology, an
important step is to examine miRNA profiles in BCSCs
and MaSCs. We report here miRNome data of MaSCs
isolated from MCF-10A, an established breast epithelial
cell line. Compared with the miRNAome data of BCSCs
sorted from breast cancer cell line MCF-7 in previous
research [26], we discussed the key miRNAs, their essen-




HeLa, NIH-3T3 and HEK-293 T cells (cryopreservation in
our lab) were cultured in Dulbecco’s MEM modified
medium (DMEM) with 10 % fetal bovine serum (FBS) at
37 °C and 5 % CO2 incubator. Before being used as feeder
cells, NIH-3T3 cells were exposed to 50 Gy of 60Co radio-
active source. Breast cancer cell line MCF-7 and normal
mammary epithelial cell line MCF-10A were obtained
from ATCC (Manassas, VA). MCF-7 cells were cultured
in minimum essential medium (Eagle), supplemented with
10 % fetal bovine serum. MCF-10A cells were cultured in
DMEM/F-12 (Hyclone, USA) supplemented with 10 %
horse serum (Cambrex, USA), 10 μg/mL insulin, 2 μg/mL
hydrocortisone, 0.01 μg/mL cholera toxin (Sigma-Aldrich,
USA) and 0.02 μg/mL epidermal growth factor (EGF)
(Sigma-Aldrich, USA).
Isolated MUC1−ESA+ subpopulation from MCF-10A cell line
When MCF-10A cell confluence reached about 80 %, single
cells were obtained by 0.25 % typsin/EDTA (Gibco, USA)
digestion, stained by MUC1-PE (BD Pharmingen, USA)
and ESA-FITC (BD Pharmingen, USA). MUC1−ESA+ sub-
population was sorted by fluorescence-activated cell sorting
(FACS, MoFlo, Dako-Cytomation, USA). The rest propor-
tion of MCF-10A cells excluding MUC1−ESA+ was also
sorted as control counterparts. Through FACS sorting,
MUC1−ESA+ subpopulation was highly purified (purity
greater than 98 %).
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2-Dimensional (2-D) clonogenic assay
Cells (200 cells per well) were seeded into a 24-well plate
with EpiCult-B serum-free (Stem Cell, USA) and 5 %
FBS and 2 × 104 irradiated NIH-3T3 cells. After incuba-
tion at 37 °C in 5 % CO2 for 8–10 days, colonies of over
50 μm in diameter were counted [27]. The colonies were
fixed with acetone: methanol (1:1), stained with Giemsa
(Sigma-Aldrich, USA), and observed and photographed
under an inverted microscope. Then clonogenic poten-
tial was calculated. Clonogenic potential (%) = colony
numbers/seeding cell numbers × 100 %. The MCF-10A
cells excluding MUC1−ESA+ were also plated as control.
3-Dimensional (3-D) tumor spheroid assay
Cells (100 cells per well) were suspended in EpiCult-B
serum-free medium and plated on top of solidified matrigel
in a 96-well plate. After 10–14 days’ culture at 37 °C in 5 %
CO2, colonies over 50 μm in diameter were counted [27].
The test was repeated four times. For immunofluorescence,
matrigel mammospheres were embedded in paraffin and
cut into slices of 7 μm in thickness for immuno-staining.
Immuno-staining of K14-DyLight594 (Biolegend, USA)
(1:100), K8-DyLight488 (Biolegend, USA) (1:100) and Dapi
(1:1000) was carried out according to their instructions.
Microarray fabrication and miRNA hybridization
Both human miRNA microarray fabrication and hybridi
zation were performed as described previously [26, 28].
Briefly, miRNA microarray from CapitalBio Corporation
(Beijing, China) included 517 mature miRNA sequences
[29]. Total RNA was extracted from MUC1−ESA+ subpop-
ulation with trizol and amplified with NCode™ miRNA
amplification system (Invitrogen, USA). After fluorescent
labeling of miRNAs, hybridization was conducted at 42 °C
overnight. Then data normalization by a normalization
factor and clustering was performed based on mean inten-
sity for inter-array comparison. For each sample, two
hybridizations were carried out, and each miRNA probe
had triplicate dots on the microarray. Significance analysis
of microarrays was performed using a two class-unpaired
comparison in the SAM procedure Version 2.1 (CapitalBio,
China). All the microarray data have been uploaded and
submitted to a public repository Gene Expression Omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE68271).
Real time RT-PCR (qRT-PCR) assay
Total RNA was extracted from sorted cells using RNeasy
Micro plus kit (Qiagen, USA), and reverse transcribed into
cDNA with standard techniques (ABI, USA). qRT-PCR
assay was performed using SYBR® Green PCR Master Mix
(ABI, USA). We followed Chen’s protocol for primer design
and qRT-PCR [30]. U6 small nuclear RNA (U6 snRNA)
was used as an internal control. Its sense and antisense
primers were 5′-ctcgcttcggcagcaca-3′ and 5′-aacgcttcac-
gaatttgcgt-3′. The chosen miRNAs included miR-200c,
miR-296, miR-21, miR-373* and miR-122a. The universal
sense primer of miRNAs is 5′-gtgcagggtccgaggt-3′. Re-
verse transcription primer and antisense primer for









tacgacacaaac-3′ and 5′-agctggagtgtgacaatggtg-3′. All
the qRT-PCR reactions were repeated no less than 3
times.
miRNA agomir transfection into BCSCs or MaSCs
MCF-7 cells were harvested and digested into single cell
suspensions. Obtained cell suspensions were stained with
the antibodies (CD24-PE, ESA-FITC and CD44-APC), and
ESA+CD44+CD24-/low BCSCs were sorted with FACS as
previously described [26]. Sorted BCSCs (purity greater
than 98 %) were suspended in EpiCult-B serum-free
medium, and lipofectamine 2000 (Invitrogen, USA)
was added together with miR-200c agomir, antagomir
(Dharmacon, USA) or miR-control for incubating
24 h. The final concentration of miR-200c agomir,
antagomir or miR-control was 30 nM. And miR-200c
agomir or antagomir transfection into MaSCs was
done in the same manner. The tests were repeated five
times.
Clonogenic ability in vivo
Transfected BCSCs were suspended in EpiCult-B
serum-free medium with 25 % matrigel and injected
subcutaneously in the mammary fat pads in syngeneic
mouse (NSG female, aged 5–6 weeks). The test group
was BCSCs transfected with miR-200c agomir with the
cell number of 0.5 K, 1 K, 5 K, 10 K, 25 K, 50 K and
100 K. The control group was BCSCs transfected with
miR-control with the cell number of 0.5 K, 1 K, 5 K
and 10 K. We also set parental BCSCs as a control. Three
mice were used for each gradient of cell inoculation. Next,
the mice were observed weekly for up to 2 months for
tumorigenesis and then sacrificed by cervical dislocation.
TIC frequency was calculated and compared using extreme
limiting dilution analysis (ELDA, http://bioinf.wehi.edu.au)
[31]. All animal procedures were carried out with the
approval of the Animal Ethics Committee of the Third
Military Medical University.
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Bioinformatics and target prediction
Chromosome localization, sequence analysis and target
prediction of the miRNAs were carried out by online
programs, picTar (http://pictar.mdc-berlin.de/), miRanda
(http://microrna.sanger.ac.uk), targetscan (http://www.
targetscan.org), and so on. The mRNAs predicted by three
algorithms at least were selected as putative targets. Then
mFold Software was used to analyze binding free energy
(△G) of hybridization between miRNAs and 3′-UTR com-
plementary sites of mRNAs. Those mRNAs combined with
miRNAs with lower free energy at both 5′-70 bp and 3′-
70 bp than their average random free energy were deemed
accessible to specific miRNAs [32, 33].
Dual luciferase reporter assay
Through searching for NCBI GenBank database, 3′-
UTR sequences of target gene with 100–120 nt in length
containing the seed sequence were synthesized. The
dangling ends of synthesized fragments were added with
XbaI restriction sites (Takara, China). We followed the
protocol of our previous work for vector reconstruction
and experimental design [34]. Briefly, dual luciferase
reporter vectors pGL3-pro and control plasmid pRL-
TK (Promega, USA) were used for the assay. Three
different 3′-UTR sequences of target gene were synthe-
sized, 3′-UTR 5′→ 3′, 3′-UTR 3′→ 5′ and 3′-UTR
5′→ 3′ without seed sequence. We cloned them into
pGL3-pro vector, respectively. The experiment was
designed as four groups: test group (pGL3-pro-UTR
5′→ 3′), Con-1 group (pGL3-pro-UTR 3′→ 5′), Con-2
group (pGL3-pro-UTR 5′→ 3′ del), and Con-3 group
(empty vector pGL3-pro). We used lipofectamine 2000
to transfect HeLa cells when cell confluence reached
70-80 % in a 24-well plate. Each well of cotransfection re-
action contained 200 ng of recombinant pGL3 plasmid,
200 ng of pRL-TK plasmid and 2.5 μL of miR-200c agomir
or antagomir. The final concentration of miR-200c agomir
or antagomir was 30 nM, 500 μL of liquid in each well.
Cells were collected after 48 h of incubation and analyzed
for luciferase activity using a dual luciferase reporter system
Promega GloMax™ 20/20 (Promega, USA). The luciferase
ratio of Firefly/Renilla represented target gene expression.
Data of each group are presented as mean ± SD (standard
deviation).
Western blot
Cytoplasmic protein was extracted according to the man-
ufacturer’s instructions (Sigma-Aldrich, USA). Western
blot was performed as described in detail in the earlier
report [35]. Primary antibodies used in this study in-
cluded anti-human programmed cell death 10 (PDCD10)
(Abcam, USA).
Lentivirus infection
Lentiviruses were produced and purified as described
previously [36]. Reconstructed PDCD10 plasmid was
generated by PCR-cloning full-length human PDCD10
cDNA (AF022385) into the EcoRI/BamHI sites of lenti-
virus vector pCDH (System biosciences, USA). Primers
for PCR are 5′-ccggaattcatgaggatgacaatggaa-3′ and 5′-
cgcggatcccaggccacagttttgaag-3′. Recombinant plasmid
was cotransfected with packaging plasmids into HEK-
293 T cells to produce lentivirus particles (Lenti-
PDCD10). Active viruses were mixed with sorted BCSCs
supplemented with 8 μg/mL Polybrene (Sigma, USA), and
seeded to a 3D matrigel culture system with EpiCult-B
serum-free medium. As for the rescue experiment, Lenti-
PDCD10, Polybrene and miR-agomir were mixed in
EpiCult-B serum-free medium beforehand, and then added
into the matrigel culture system. The final concentration of
miR-agomir or miR-control was 30 nM.
Results
Stemness assessment of MUC1−ESA+ cells
FACS analysis showed that MUC1−ESA+ subpopulation in
MCF-10A cells accounted for 1–1.5 % (Fig. 1a). For 2-D
clonogenic assay after 10 days of culture, sorted MUC1−
ESA+ cells showed multiple morphological colonies, at least
three types of mammary epithelial cell colonies including
pure luminal colonies, pure myoepithelial colonies and
mixed colonies. Immuno-staining confirmed that mixed
colonies had multi-component including myoepithelial cells
(K14-DyLight594) and luminal cells (K8-DyLight488). The
rest MCF-10A cells excluding MUC1−ESA+ (non-stem
MCF-10A) showed a unique type of colonies (Fig. 1b).
The clonogenic potential of MUC1−ESA+ cells was 61.50
± 3.77 %. However, the clonogenic potential of non-stem
MCF-10A cells was 53.50 ± 3.44 %. MUC1−ESA+ cells had
significantly higher clonogenic potential (P < 0.05, Fig. 1c).
After 10 days of 3-D matrigel culture, MUC1−ESA+ cells
also grew into mammospheres. After immuno-staining
with myoepithelial marker K14-DyLight594 (1:100), mam-
mospheres showed ductal-like structure (Fig. 1d). How-
ever, mammospheres of non-stem MCF-10A cells did not
show duct-like structures (Additional file 1: Figure S1a).
Additionally, mammospheres on day 10 were digested and
analyzed by FACS, showing that the proportion of
MUC1−ESA+ cells increased to 8.34 % (Fig. 1a). These
results indicated that MUC1−ESA+ cells possessed
stemness properties of multi-potential differentiation
and clonogenesis. MaSCs could be obtained by sorting
MUC1−ESA+ subpopulation from MCF-10A cell line.
miRNA profile of BCSCs distinct from MaSCs
The internal control U6 snRNA dots on all microarrays
exhibited consistent signal intensity and the signal of all
the detected dots in the replicate microarrays showed a
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high correlation efficiency (R = 0.9616 ± 0.0244), indicating
the repetitiveness and reproducibility of the microarrays.
Collectively, a profile of 72 mature miRNAs was detected
(with signal value above 800) in MaSCs (Fig. 2a).
In our previous study, we obtained miRNA profile in
BCSCs from breast cancer cell line MCF-7 [26]. Since
it is hypothesized that BCSCs initiate from MaSCs,
BCSC-related miRNAs distinct from MaSCs could
clarify the mechanism of mammary tumorigenesis. We
compared miRNome data between BCSCs and MaSCs,
and obtained 12 differential miRNAs with fold change
more than 3 times. Among them, 8 miRNAs were upreg-
ulated in BCSCs (miR-25, let-7f, miR-342, miR-103, miR-
21, miR-16, miR-200c and miR-122a) and 4 miRNAs were
downregulated in BCSCs (miR-345, miR-155, miR-205
and miR-494) (Table 1).
Verification of miRNA microarray by qRT-PCR assay
To verify the results of miRNA microarray, miRNA qRT-
PCR assay was performed. Besides the miR-200c, miR-21
and miR-122a upregulated in BCSCs compared with
MaSCs, we also chose miR-296 and miR-373* which were
respectively downregulated and upregulated in BCSCs
compared with paternal MCF-7 cells in our prior study
[26], and highly associated with the development of human
embryonic stem cells [37, 38]. Thus, a total of 5 miRNAs
(miR-200c, miR-296, miR-21, miR-373* and miR-122a)
were selected to qRT-PCR assay among three types of cells,
BCSCs, MaSCs and MCF-7. The relative quantitative
(RQ) miRNA expression of MCF-7/BCSCs and MaSCs/
BCSCs were shown as mean ± SD (Table 2, Fig. 2b).
Amplification curve of representative miRNAs were
also displayed (examples in Fig. 2c and d). As a result,
there were 10 qRT-PCR reactions of 5 miRNAs be-
tween BCSCs, MaSCs and MCF-7 cells. Among them, 8
reactions were consistent with miRNA microarray ex-
cept for miR-296 and miR-200c in MCF-7/BCSCs
(Table 2). Collectively, 80 % consistency in these data
indicated that the results of miRNA microarray in our
study were highly reliable. According to our hypothesis
Fig. 1 Tumor-initiation ability of MUC1−ESA+ cells sorted from mammary epithelium. a. MUC1−ESA+ subpopulation accounts for 1.35 % of MCF-10A cells
when being sorted, and 8.34 % in serum-free culture on day 10. b. In the 2-D culture, sorted MUC1−ESA+ cells show three types of colonies including
myoepithelial, luminal and mixed colonies, while the control cells (MCF-10A excluding MUC1−ESA+) displayed a unique type of colonies. c. The number
of colonies and histogram of panel B (*, compared with the control, n= 6, P< 0.05). d. In the 3-D matrigel culture, sorted MUC1−ESA+ cells proliferate into
colonies with duct-like structures and myoepithelial marker K14-DyLight 594 expression
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that MaSCs is the source of BCSCs which proliferate
and differentiate into breast cancer cells, miRNAs with
consecutive changes from MaSCs to BCSCs to MCF-7
cells would more likely be the essential regulators of
self-renewal of BCSCs. Thus, miR-373*, miR-21 and
miR-200c could be the candidates. Here, we chose
miR-200c for following research since it has been
proven to be a critical regulator of BCSCs in primary
tumor tissues [10].
Role of miR-200c in regulating stemness of BCSCs
and MaSCs
To test biological function of miR-200c, we introduced
miR-200c agomir and miR-200c antagomir into both
BCSCs and MaSCs, respectively. In qRT-PCR assay,
miR-200c was expressed much higher after miR-200c
agomir transfected into BCSCs and MaSCs than the
control (P < 0.01) analyzed by Tamhane’s test or non-
parametric statistics analysis (SPSS 18.0). miR-200c
expression reached 281 and 408 times higher in
BCSCs and MaSCs, respectively. And miR-200c antag-
omir significantly downregulated miR-200c expression
in BCSCs and MaSCs than the control (P < 0.01). The
fold changes were 0.40 and 0.52, respectively (Fig. 3a).
To test whether miR-200c agomir is related to self-
renewal of MaSCs and BCSCs, we utilized the matrigel
3-D culture system. From seeding cells of the same
number, MaSCs transfected with miR-200c agomir
resulted in significantly fewer mammospheres (28.8 ±
2.05) (P < 0.01, n = 5), and miR-200c antagomir signifi-
cantly increased mammospheres (61.80 ± 5.54) (P <
0.01, n = 5) than those transfected with miR-control
(42.20 ± 3.35) (Fig. 3b). The similar result was found in
Fig. 2 Microarray analysis of miRNA expression in MaSCs and qRT-PCR verification. a. Duplicate microarray analyses of miRNA expression in MaSCs.
Triplicate dots on the microarray exhibit consistent signal intensity. b. Relative quantitative (RQ) expressions of 5 miRNAs in MCF-7/BCSCs/MaSCs shown
as mean ± standard deviation (SD). (*, The expressions of miR-21, miR-296 and miR-200c are significantly higher in MCF-7 than in
BCSCs. **, the expression of miR-373* is significantly higher in MaSCs than in BCSCs). c. Amplification curve of miR-200c in MCF-7/
BCSCs/MaSCs. Comparison of miR-200c expressions tends to be MaSCs < BCSCs < MCF-7. d. Amplification curve of miR-21 in MCF-7/
BCSCs/MaSCs. Comparison of miR-21 expressions tends to be MaSCs < BCSCs < MCF-7







miR-122a 4.731 miR-494 0.099
miR-200c 4.022 miR-205 0.100
miR-16 3.703 miR-155 0.319
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Table 2 Relative expression of miRNAs between MCF-7/BCSCs/MaSCs
miRNAs △CT RQ Chip △CT RQ Chip
BCSCs-MCF7 MCF7/BCSCs MCF7/BCSCs MaSCs-BCSCs MaSCs/BCSCs MaSCs/BCSCs
U6 RNA 3.303 ± 0.297 8.154 ± 0.516 −0.937 ± 0.182 0.553 ± 0.064
miR-21 7.390 ± 0.089 14.052 ± 0.753 4.75 3.127 ± 0.809 0.259 ± 0.096 0.272
miR-296 4.990 ± 0.255 3.133 ± 0.830 0.191 −0.427 ± 0.197 1.403 ± 0.310 1.025
miR-373* 0.240 ± 0.615 0.150 ± 0.052 0.162 1.607 ± 0.134 5.092 ± 0.310 1.696
miR-200c 4.987 ± 0.290 2.913 ± 0.278 0.581 −1.497 ± 0.298 0.705 ± 0.106 0.249
miR-122a 0.280 ± 0.759 0.158 ± 0.064 0.020 −1.803 ± 0.412 0.585 ± 0.091 0.211
Fig. 3 miR-200c inhibits the self-renewal of BCSCs and MaSCs. a. In qRT-PCR assay, miR-200c agomir significantly upregulates miR-200c expression in both
BCSCs and MaSCs (*, P< 0.01); miR-200c antagomir significantly downregulates miR-200c expression in both BCSCs and MaSCs (**, P< 0.01). b. In MaSCs,
miR-200c agomir significantly decreases the colonies (P< 0.01, n= 5) while miR-200c antagomir significantly increases the colonies (P< 0.01, n= 5). c. In
BCSCs, miR-200c agomir significantly decreases colonies (P< 0.01, n= 5) while miR-200c antagomir significantly increases colonies (P< 0.01, n= 5). d. No
tumor was observed in the test group (miR-200c agomir) in 2 months after inoculation of 10 K cells. In the miR-control group and parental BCSC group,
average tumor volumes are 137.4 ± 13.7 mm3 and 124.1 ± 18.6 mm3, respectively. e. A limiting dilution assay for tumorigenesis in vivo and TIC Frequency
calculation. f. Surface markers (ESA+CD44+CD24-/low) of BCSCs were detected on day 10 after transfecting miR-agomir or miR-control
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BCSC experiment. BCSCs transfected with miR-200c
agomir resulted in significantly fewer mammospheres
(22.2 ± 1.92) than those transfected with miR-control
(40.60 ± 3.05) (P < 0.01, n = 5). In contrast, miR-200c
antagomir significantly increased mammospheres (60.80 ±
5.40) (P < 0.01, n = 5, Fig. 3c). These results suggest that
miR-200c could inhibit the self-renewal of both MaSCs and
BCSCs.
Next, to directly test whether overexpression of miR-200c
could affect tumor initiating ability of BCSCs in vivo, we
performed limiting dilution assay for mammary tumors.
Basically, BCSCs transfected with miR-200c agomir gave
rise to smaller tumors than the control at the same number
of inoculation. In gradient assay, tumors could be observed
in every group when 10 K BCSCs transfected with miR-
control were inoculated subcutaneously, while 10 K BCSCs
transfected with miR-200c agomir could not grow into a
tumor. The average tumor volumes at two months were
124.1 ± 18.6 mm3 and 137.4 ± 13.7 mm3 in 10 K parental
BCSCs and miR-control transfected BCSCs, respectively
(Fig. 3d). To reach a similar tumorigenicity, the quantity of
required BCSCs transfected with miR-control was 10 K
while that of BCSCs transfected with miR-200c agomir was
100 K. We calculated the TIC frequency of these groups
by ELDA in addition to specifying the inoculation cell
numbers and tumor growth. As a result, miR-200c agomir
led to 9.59 times lower tumor initiating ability compared
with miR-control (1/51160 vs. 1/5334) (Fig. 3e). Taken to-
gether, miR-200c downregulation is required by BCSCs
for survival and expansion both in vitro and in vivo.
Therefore, we wondered if miR-200c had some effects on
sustaining the “stemness” of BCSCs. We detected the sur-
face markers (ESA+CD44+CD24-/low) of BCSCs on day 10
after transfecting miR-agomir or miR-control. The propor-
tion of stem cells decreased in the miR-200c transfection
group compared with that in the miR-control transfection
group (7.60 vs 13.37 %, Fig. 3f).
Verification of PDCD10 as miR-200c target
We listed 24 potential targets of miR-200c, including
TMEFF2, TIEG, TGFB1I4, TDE2, TCF8, TCF2, TBP,
SYVN1, PDCD10, SFRS2, SFRS1, PTPN13, RAP2C,
RAP1B, RAB7, RAB2, GATA4, FGFR2, ESRRG, EPS8,
EIF5B, EIF3S1, EIF2B5 and APRIN. These potential targets
involved in oncogenes, anti-oncogenes, transcription factors
and DNA repair, cell cycle regulation, miRNA processing
and signal transduction. Then mFOLD analysis showed
that two of them, PDCD10 and TCF2, could be the putative
targets of miR-200c. The binding free energies between
PDCD10 and miR-200c at both 5′-70 bp and 3′-
70 bp were −15.54 and −15.70, respectively, lower than
average random free energy of PDCD10 (−14.59). And
the binding free energies between TCF2 and miR-200c at
both 5′ 70 bp and 3′ 70 bp were −15.12 and −15.20,
respectively, lower than average random free energy of
TCF2 (−14.28). Also, miR-200c showed broadly con-
served binding sites with PDCD10 and TCF2 in different
species (Fig. 4a). Thus, PDCD10 and TCF2 were chosen
for further study.
For miR-200c target PDCD10 verification, the ratios
of firefly/renilla in dual luciferase assaywere similar
between reverse, deletion and empty vector control
groups (13.99 ± 2.50, 13.37 ± 1.73 and 12.36 ± 1.44),
whereas the relative luciferase activity (6.40 ± 0.73)
was significantly lower in the test group (P < 0.05)
(Fig. 4b and c). For miR-200c target TCF2 verification,
no significant difference was found between the test
group and the three control groups (Fig. 4b and c).
The protein change of PDCD10 during miR-200c agomir
transfection had been tested by western blot. Compared
with the control group (miR-control), PDCD10 proteins
were dramatically reduced in BCSCs and MaSCs, respect-
ively (Fig. 4d).
To sufficiently prove that PDCD10 is the target of
miR-200c, we performed more experiments. First, since
miR-200c agomir inhibited mammospheres of BCSCs and
MaSCs, and miR-200c antagomir demonstrated opposite
effects, overexpresion of PDCD10 should promote the
“stemness” of BCSCs. Actually, the experiment of upregu-
lated PDCD10 by lentivirus vector (Fig. 4d) showed more
mamaospheres in BCSCs (60.40 ± 5.03) as expected com-
pared with empty vector transfection (42.20 ± 3.49) (P <
0.01, n = 5, Fig. 4e). Second, rescue experiment was deliv-
ered in tumor spheroid assay of miR-200c agomir in
BCSCs. BCSCs cotransfected with Lenti-PDCD10 and
miR-200c agomir showed more mammospheres (52.60 ±
4.67) compared with BCSCs transfected with miR-200c
agomir alone (26.40 ± 2.07) (P < 0.01, n = 5, Fig. 4e). From
these results, we believe that PDCD10 is responsible for
miR-200c-mediated decrease in mammospheres in BCSCs.
Discussion
As molecules that regulate biological growth and devel-
opment, miRNAs show aberrant expression in many
malignant tumors. MiRNAs also play a vital role in main-
taining self-renewal and multi-directional differentiation of
human embryonic stem cells and other adult stem cells
[20, 39, 40]. These intriguing questions remain to be an-
swered in looking for the source of breast cancer. Although
some reports showed that differentiated breast cancer cells
could be reprogrammed into BCSCs [41], it is hypothesized
that BCSCs could initiate from accumulating mutations of
MaSCs [11–13]. For example, there are considerable simi-
larities between basal-like and BRCA1-mutated breast
cancers, and these cancers arise from transformation of a
basal cell in normal breast epithelium through BRCA1
dysfunction [42]. Therefore, screening of miRNA profiles
in BCSCs and MaSCs seems significant to elucidate the
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role and mechanism of miRNAs in tumorigenesis of breast
cancer.
MUC1−/ESA+ cells have been demonstrated to function
as stem cells of terminal duct lobular units in the human
breast [15]. We successfully sorted MUC1−ESA+ cells from
MCF-10A cells. The subsequent experiments showed that
MUC1−ESA+ cells had the ability to form both acinar- and
duct-like colonies, indicating their stemness and capability
of multi-directional differentiation. To our best knowledge,
it is the first report to isolate MaSCs from a human mam-
mary cell line.
Growing evidence shows the involvement of miRNAs
in mammary biology and breast cancer. For instance,
miR-206 expression was higher in ERalpha-negative MB-
MDA-231 cells than in ERalpha-positive MCF-7 cells [43],
and enforced expression of miR-125a or miR-125b led to
coordinate suppression of ERBB2 and ERBB3 in the human
breast cancer cell line SKBR3 [44]. Furthermore, miR-27b
could be one of the causes of up-regulation of the drug-
metabolizing enzyme CYP1B1 in cancerous tissues [45].
Then, as a tumor suppressor in breast cancer cells, miR-
17-5p regulated breast cancer cell proliferation by inhibit-
ing the translation of AIB1 mRNA [46]. Ma et al. [47]
found that the expression of miR-10b was significantly
increased in metastatic breast cancer cell line, indicating
the possible role of miR-10b in facilitating metastasis. The
down-regulated expression of miR-125b in breast cancer
cells suggests the possible anti-tumor effect of miR-125b
[40]. As for miR-200c, several reports showed that miR-
200c played important roles in all kinds of biological
features in breast cancer cells. For instance, miR-200c
upregulation in MCF-7 led to reduced expression of
transcription factor 8 and increased expression of E-
cadherin [48]. The low- or non-expression of miR-200c
Fig. 4 Verification of PDCD10 as a target of miR-200c. a. The binding sites of PDCD10 and TCF2-to miR-200c, and mFOLD analysis of free energy. b.
Histogram of dual luciferase assay (a, compared with test group, P< 0.05). c. Experimental data of dual luciferase assay (a, compared with control groups,
P< 0.05). d. In western blot assay, compared with empty vector (EV), Lenti-PDCD10 dramatically increases PDCD10 expression in BCSCs, and compared
with miRNA control (miR-con), miR-200c agomir (miR-ag) dramatically decreases PDCD10 expression in BCSCs and MaSCs. e. In the 3-D matrigel culture,
miR-200c agomir decreases, and Lenti-PDCD10 increases mammospheres of BCSCs compared with miR-control (P < 0.01, n= 5). Lenti-PDCD10 rescues
mammospheres inhibited by miR-200c agomir (P < 0.01, n= 5)
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may lead to the invasion and migration of breast cancer
cells [49, 50]. Dykxhoorn et al. [51] found in a mouse
model of breast cancer that miR-200 family could sup-
press the expression of Zeb2, a transcription inhibiting
gene, and enhance the expression of E-cadherin, thus
inhibiting endothelial mesenchymal transformation
(EMT). In treatment of breast cancer cells, miR-200c
was also reported to sensitize apoptosis [52], chemo-
therapy [53, 54], radiotherapy [55, 56] and trastuzu-
mab targeted therapy [57].
Recently, a few studies have reported miRNA expression
in BCSCs. Shimono [10] found that 37 miRNAs were up-
regulated or downregulated in BCSCs compared with non-
tumorigenic breast cancer cells. In this report, miR-200c
played important regulatory roles in maintaining the func-
tion of BCSCs by downregulating BMI 1 and in inhibiting
EMT. Another research showed that let-7 downregulation
in human BCSCs affected the self-renewal ability of stem
cells via regulating its target gene Ras, and changed the
differentiation ability of stem cells by regulating HMGA2
expression [21]. However, there are few reports on the
different miRNA profiles between MaSCs and BCSCs.
In this study, we successfully obtained miRNome data of
BCSCs and MaSCs, and found 12 differentially expressed
miRNAs. Thereafter, miR-200c was chosen and analyzed
for its function in regulating self-renewal of MaSCs and
BCSCs. By high-throughput miRNA microarray and qRT-
PCR assay, miR-200c in BCSCs was confirmed to be
downregulated 2.913 times compared with that in MCF-7
and upregulated 1.418 times compared with that in MaSCs
(Table 2). Consecutive upregulation of miR-200c from
MaSCs to BCSCs to MCF-7 implied the essential role of
miR-200c in the initiation of mammary tumor. Functional
assays indicated the critical role of miR-200c in suppressing
the self-renewal of human BCSCs and MaSCs. In BCSC
study, we not only conducted the clonogenic assay in vitro,
but also calculated TIC frequency in vivo. By detecting the
surface markers (ESA+CD44+CD24-/low) in vitro, we found
that miR-200c decreased the proportion of stem cells.
However, as the agomir of miR-200c could not be inserted
into genomic DNA like lentivirus vector, its function was
time-dependent in vivo. Theoretically, the transfected
BCSCs would differentiate into tumor cells in formed tu-
mors several weeks later and return to the same proportion
as was in the control tumors [58]. We could not determine
whether miR-200c had an effect on the prevalence of the
stem cell population in these tumors. Nevertheless, both in
vitro clonogenic assay and in vivo tumorigenesis assay
showed that miR-200c functioned as an anti-oncogene.
Collectively, the increase of miR-200c in MCF-7 could
result from the stemness loss of BCSCs and their uncon-
trollable proliferation and differentiation.
In the present research, miR-200c was found downregu-
lated 1.808 times in MaSCs compared with parental MCF-
10A cells (GSE68271, Additional file 1: Figure S1b). Since
ectopic expression of miR-200c suppressed the tumorigenic
ability of BCSCs, the downregulation of miR-200c in
MaSCs suggests that MaSCs also possess a tendency of
tumorigenesis compared with MCF-10A cells. These results
are consistent with the findings of other groups [6, 59, 60].
Interestingly, we found that miR-200c level was modestly
lower in MaSCs than in BCSCs (Fold Change 0.705). It is
appreciated that the tumorigenic ability of CSCs is stronger
than that of normal stem cells, and high activity of self-
renewal does not completely correlate with tumorigenesis
[6, 59, 60]. Our results indicate that miR-200c plays a crit-
ical role in the self-renewal of MaSCs and BCSCs. To our
best knowledge, this is the first time to find that miR-200c
could be involved in malignant transformation of MaSCs
into BCSCs at the level of cell lines. Our findings here sup-
port previous reports that miR-200c is critical in regulating
the self-renewal of BCSCs in primary tumor tissue [10]. Of
course, we did not verify these findings in MCF-10A de-
rived tumor cell MCF10DCIS.com, but a future research
would be expected.
Furthermore, we searched and verified PDCD10, a new
target of miR-200c in the present study. Bioinformatics and
prediction programs have become preferential methods to
explore the function of miRNAs [61, 62]. The genes pos-
sibly regulated by BCSC-related miRNAs should be in-
volved in both tumorigenesis and stem cell maintenance.
PDCD10 is an apoptosis-related gene of 1,218 bp in length
located on chromosome 3q26.1, highly conserved in differ-
ent species. As an important apoptosis regulator, PDCD10
is upregulated in various tumors [63–65]. PDCD10 is also
involved in angiogenesis and vascular reconstruction and
closely associated with the prognosis of cancer patients
[66]. In dual-luciferase reporter assay and western blot, we
observed that miR-200c inhibited PDCD10 expression in
both BCSC and MaSC subpopulations. In an ischemic pre-
conditioning (IPC) model, PDCD10 was confirmed to be
significantly reduced in preconditioned mesenchymal stem
cells (MSCs) [67]. In the present study, PDCD10 promoted
the self-renewal of BCSCs. Since miR-200c inhibited the
stemness of BCSCs/MaSCs and PDCD10 simultaneously,
PDCD10 could be a possible mechanism mediated by miR-
200c in stemness regulation of breast tumorigenesis and
malignant transformation.
Recently, reports showed that both small interfering
RNAs (siRNAs) and miRNAs could have off-target effects
(OTEs) [68, 69]. In the present study, we obtained an over-
expression of miR-200c to an extent of 300–400 times.
However, there was no evidence of OTEs, since miR-200c
antagomir showed opposite effects against miR-200c ago-
mir in functional analysis. Moreover, almost at the same
time as our research, an article preliminarily demonstrated
that PDCD10 was a target of miR-200C, in which only
dual-luciferase method was used [70]. In our research, we
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also performed verification experiments including western
blot, PDCD10 overexpression and rescue experiment to
confirm it was a real target of miR-200c. Thus, the present
study indicates that PDCD10 is a new mechanism under-
lying miR-200c stemness maintenance in both MaSCs and
BCSCs.
The BCSC-related miRNAs mentioned above could
provide novel insights into BCSCs initiation, self-renewal
and stemness maintenance. Future work should include
verification of the putative targets of other BCSC-related
miRNAs identified here.
Conclusions
In summary, we obtain the miRNome data of BCSCs and
MaSCs, and a series of functional researches show that
PDCD10 is a target gene of miR-200c and also a possible
mechanism by which miR-200c regulates the stemness of
BCSCs and MaSCs. Our identification of BCSC-related
miRNAs should be a starting point to explore the mech-
anism of malignant transformation of MaSCs into BCSCs,
which may provide new insights into the complex picture
of BCSCs and assist cancer biologists and clinical oncolo-
gists in designing and testing novel therapeutic strategies.
Additional file
Additional file 1: Figure S1. Additional materials. a. In the 3-D
matrigel culture, MCF-10A cells excluding MUC1−ESA+proliferate
into colonies. Mammospheres of non-stem MCF-10A cells do not
show duct-like structures. b. miR-200c is downregulated 1.808 times
in MaSCs compared with non-stem MCF-10A cells. (TIFF 1147 kb)
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